Nilotinib
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Gastrointestinal Stromal Tumors
Conditions
Gastrointestinal Stromal Tumors
Trial Timeline
Aug 29, 2008 → Dec 18, 2024
NCT ID
NCT00756509About Nilotinib
Nilotinib is a approved stage product being developed by Novartis for Gastrointestinal Stromal Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00756509. Target conditions include Gastrointestinal Stromal Tumors.
What happened to similar drugs?
5 of 20 similar drugs in Gastrointestinal Stromal Tumors were approved
Approved (5) Terminated (4) Active (11)
🔄Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04559555 | Pre-clinical | Completed |
| NCT04498871 | Pre-clinical | Completed |
| NCT04518644 | Pre-clinical | Completed |
| NCT02774512 | Phase 1 | Withdrawn |
| NCT02546674 | Approved | Completed |
| NCT02115386 | Phase 3 | Terminated |
| NCT02353728 | Phase 2 | Completed |
| NCT02108951 | Phase 3 | Terminated |
| NCT01844765 | Phase 2 | Completed |
| NCT01744665 | Phase 2 | Completed |
| NCT01863745 | Phase 2 | Completed |
| NCT03332511 | Approved | Completed |
| NCT01743989 | Phase 3 | Completed |
| NCT01735955 | Approved | Completed |
| NCT01698905 | Phase 2 | Completed |
| NCT01562847 | Pre-clinical | UNKNOWN |
| NCT01077544 | Phase 1 | Completed |
| NCT01254188 | Phase 3 | Completed |
| NCT01274351 | Phase 2 | Completed |
| NCT01270893 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Gastrointestinal Stromal Tumors